WO1999033412A1 - Stentless bioprosthetic heart valve with coronary protuberances - Google Patents
Stentless bioprosthetic heart valve with coronary protuberances Download PDFInfo
- Publication number
- WO1999033412A1 WO1999033412A1 PCT/US1998/026344 US9826344W WO9933412A1 WO 1999033412 A1 WO1999033412 A1 WO 1999033412A1 US 9826344 W US9826344 W US 9826344W WO 9933412 A1 WO9933412 A1 WO 9933412A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bioprosthesis
- coronary
- aortic
- segment
- segments
- Prior art date
Links
- 0 C*1=CN**1 Chemical compound C*1=CN**1 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/24—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
- A61F2/2412—Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0096—Markers and sensors for detecting a position or changes of a position of an implant, e.g. RF sensors, ultrasound markers
- A61F2250/0097—Visible markings, e.g. indicia
Definitions
- the present invention pertains generally to medical devices and methods, and more particularly to a bioprosthetic heart valve device and related methods for surgical implantation of such bioprosthetic device.
- Heart valve replacement surgeries have been performed in human beings for many years. Most frequently, these valve replacement procedures are utilized to replace the mitral or aortic valves of patients who suffer from valvular heart disease.
- aortic valve In particular, surgical replacement of the aortic valve has proven to be a successful mode of treatment of patients who are diagnosed with a) obstruction (i.e., stenosis) of the aortic valve or b) leakage (i.e., regurgitation, incompetence or insufficiency) of the aortic valve.
- a) obstruction i.e., stenosis
- leakage i.e., regurgitation, incompetence or insufficiency
- symptoms of both obstruction and leakage are present, this being known as “mixed disease" or “combined lesions”.
- mixed disease or “combined lesions”.
- These types of aortic valvular heart disease may be caused by a number of factors, including congenital deformations, infections, degenerative calcification, and certain rheumatological disorders.
- Surgical replacement of the aortic valve is typically performed under general anesthesia, with full cardiopulmonary bypass.
- An incision is made in the aorta adjacent to the heart, and the leaflets of the endogenous aortic valve are removed along with any calcified surrounding tissue, thereby creating an annular opening (i.e. the "aortic annulus") at the site previously occupied by the endogenous aortic valve.
- a prosthetic aortic valve is selected and sutured into the aortic annulus, as a prosthetic replacement for the surgically- removed endogenous valve.
- prosthetic aortic valves have heretofore included mechanical valves as well as valves formed of preserved animal tissue (i.e., "bioprosthetic" valves).
- bioprosthetic valves some (known as “stented” bioprosthetic valves) incorporate a man-made stent or support frame upon which the preserved biological tissue is mounted.
- Others (known as “stentless” bioprosthetic valves) do not include any man-made stent or support frame, and are formed entirely of preserved biological tissue.
- Tissues for use in bioprosthetic heart valves are typically harvested from the hearts of donor animals and such tissues typically contain large amounts of connective tissue proteins (e.g., collagen and elastin).
- the desired tissues After the desired tissues have been harvested from the donor animals, they undergo a chemical "fixing" process wherein the connective tissue proteins within the tissue are exposed to one or more chemical cross linking agents capable of forming chemical cross linkages between amino groups present on the connective tissue protein molecules.
- chemical cross linking agents include: formaldehyde, glutaraldehyde, dialdehyde starch, hexamethylene diisocyanate and certain polyepoxy compounds.
- Examples of commercially available stented bioprosthetic valves include the Carpentier-Edwards®, PERIMOUNTTM Pericardial Bioprosthesis (Baxter Healthcare Corporation, Edwards CNS Division, Post Office Box 11150, Santa Ana, California 92711-1150) as well as the Carpentier-Edwards® Porcine Bioprosthesis (Baxter Healthcare Corporation, Edwards CNS Division, Post Office Box 11150, Santa Ana, California 92711-1150).
- stentless bioprosthetic valves examples include the Edwards PrimaTM Stentless Bioprosthesis (Baxter Edwards AG, Spierstrasse 5, CH-6848 Horw, Switzerland), the Medtronic FreestyleTM Aortic Root Bioprosthesis (Medtronic, Inc. 7000 Central Avenue ⁇ E, Minneapolis, Minnesota 55432-3576) and the St. Jude TorontoTM SPV Stentless Bioprosthesis (St. Jude Medical, Inc. One Lillehei Plaza, St. Paul, Minnesota 55117).
- Edwards PrimaTM Stentless Bioprosthesis Baxter Edwards AG, Spierstrasse 5, CH-6848 Horw, Switzerland
- Medtronic FreestyleTM Aortic Root Bioprosthesis Medtronic, Inc. 7000 Central Avenue ⁇ E, Minneapolis, Minnesota 55432-3576
- St. Jude TorontoTM SPV Stentless Bioprosthesis St. Jude Medical, Inc. One Lillehei Plaza, St. Paul, Minnesota 55117.
- the stentless bioprosthetic valves may offer superior hemodynamic performance when compared to their stented counte ⁇ arts, due to the absence of flow restrictions which can be created by the presence of a stent and/or sewing ring. Also, the stentless bioprosthetic valves may exhibit better post- implantation durability than the stented bioprosthetic valves, because they provide a more flexible structure which serves to dissipate stress during the cardiac cycle.
- At least one of the previously available aortic bioprostheses has included a segment of the donor animal's ascending aorta, along with ligated remnants of the donor's coronary arteries extending outwardly therefrom.
- the coronary artery remnants included in this bioprosthesis have been ligated prior to fixation, the lumens of these coronary artery segments are substantially collapsed and occluded. As a result, it is typically necessary for the surgeon to trim away a substantial portion of each coronary artery remnant, prior to anastomosis of the patient's endogenous coronary arteries thereto.
- a new stentless aortic bioprosthesis which includes coronary artery remnants which have been fixed in an unligated, natural configuration, such that the lumens of such coronary artery remnants remain patent, and the patient's endogenous coronary arteries may be anastomosed directly thereto.
- a stentless aortic bioprosthesis having patent coronary artery protuberances, and related methods for surgical implantation of such bioprosthesis.
- a stentless heart valve bioprosthesis formed of tanned biological tissue, comprising: an aortic segment having a wall, an inflow end, an outflow end, and a lumen extending therethrough; right and left coronary artery segments extending outwardly from said aortic segment, said coronary artery segments having open coronary lumens which extend longitudinally therethrough, such that some of the blood which enters the lumen of the aortic segment may flow outwardly through said coronary lumens; and, a plurality of valve leaflets disposed within said aortic segment, said valve leaflets being alternately moveable between i) open positions whereby blood is permitted to flow in a first direction through the lumen of said aortic segment; and ii) closed
- mandrel members such as short segments of plastic tubing may be inserted into the lumens of the coronary artery segments, prior to tanning of the tissue, to maintain the patency of the lumens of the coronary artery segments.
- Ligatures may be tied about the coronary artery segments to hold the mandrel members in place during the tanning (i.e., chemical fixation) process. The mandrel members and any accompanying ligatures may then be removed after completion of the tanning process.
- a method of surgical implantation of an aortic bioprosthesis of the foregoing character to effect a "total root" aortic valve replacement generally comprises the steps of:
- a method of surgical implantation of an aortic bioprosthesis of the foregoing character to effect replacement of a defective pulmonary valve generally comprises the steps of:
- aortic bioprosthesis of the foregoing character to effect "mini-root or "sub-coronary" replacement of a malfunctioning aortic valve.
- mini-root and sub-coronary aortic applications of the bioprosthesis are carried out in accordance with known techniques, by selectively cutting away distal portion(s) of the bioprosthesis and using the remaining portion of the bioprosthesis to carry out a mini-root or sub-coronary aortic implantation procedure.
- Figure 1 is a side perspective view of a stentless aortic bioprosthesis of the present invention having a handle-connection fixture mounted on the outflow end thereof.
- Figure 2 is a bottom perspective view of the stentless aortic bioprosthesis of Figure 1.
- Figure 3 a is a plan view of the inflow end of a stentless aortic bioprosthesis of the present invention.
- Figure 3b is a plan view of the outflow end of a stentless aortic bioprosthesis of the present invention.
- Figure 4 is a longitudinal section view of the aortic bioprosthesis, through line 4-4 of Figure 1.
- Figures 5a-5c are step-wise illustrations of a preferred technique for performing a full-root replacement of a defective aortic valve with a stentless aortic bioprosthesis of the present invention.
- a stentless aortic bioprosthesis 10 in accordance with this invention.
- This aortic bioprosthesis 10 is formed of a preserved segment of mammalian aorta 12 having an inflow rim or inflow end IE, an outflow rim or outflow end OE and the donor animal's aortic valve leaflets 20 positioned therewithin. Segments of the donor animal's right and left main coronary arteries 14a, 14b extend from the aortic segment 12, and such coronary artery segments 14a, 14b have open, patent lumens extending therethrough.
- the aortic bioprosthesis 10 of the present invention is preferably of porcine origin.
- the coronary artery segments 14a, 14b are trimmed to a desired length, such as 1-6 mm and preferably as long as possible (i.e., up to the first coronary bifurcation present on each main coronary artery of the donor animal). Thereafter internal or external support members are inserted of attached to the coronary segments 14a, 14b to maintain patency of the coronary segment lumens 15a, 15b during subsequent tanning.
- mandrel members 16 which are sized and configured to be inserted into the lumens 15 a, 15b of the coronary artery segments 14a, 14b, as shown in figure 1.
- Such mandrel members 16 may comprise solid members of generally cylindrical configuration, or may comprise segments of tubular members as specifically shown in the drawings, such tubular members having bores 17 extending longitudinally therethrough. The presence of such bores 17 in the tubular mandrel members 16 can be used as passageways for pins or support members which are used to hold or suspend the bioprosthesis 10 during the tanning process.
- ligatures 18 may tied about the coronary artery segments 14a, 14b following insertion of the mandrel members 16 thereinto, to frictionally retain the mandrel members 16 within the coronary artery segments 14a, 14b.
- the mandrel members 16 are formed of silicone tubing, but they may be formed of other materials such as polyurethane, polyester, polytetraflouroethylene (PTFE), polyethylene, stainless steel, titanium or a metal alloy.
- the bioprosthesis 10 having the mandrel members 16 inserted in its coronary segments 14a, 14b is then exposed to a chemical agent (i.e., a fixative agent or tanning agent) which will form chemical cross linkages between connective tissue protein molecules present in the tissue of the bioprosthesis 10.
- a chemical agent i.e., a fixative agent or tanning agent
- the chemical tanning agents which are useable for this pu ⁇ ose, formaldehyde, dialdehyde starch, hexamethylene diisocyanate and certain polyepoxy compound(s), as well as combinations of these agents.
- the presently preferred embodiment, shown in the drawings, is by immersion in a solution of 0.625% HEPES buffered glutaraldehyde at pressures of less than approximately 10 mmHg, as described in detail in copending United States Patent Application Serial No. (TBD), entitled System, Apparatus and Method for Chemical Fixation of Stentless Cardiac Valvular Bioprostheses, which is hereby expressly incorporated by reference.
- the bioprosthesis 10 is removed from the tanning solution and the internal or external support members (e.g., mandrel members 16) are removed.
- the internal or external support members e.g., mandrel members 16
- such ligatures 18 will typically be removed prior to extraction of the mandrel members 16.
- any distal portions 19 of coronary artery segments 14a, 14b of length L 2 located beneath or distal to the ligatures 18 may be cut away and discarded, so as to leave remaining coronary segments 14a, 14b of length Lj and of substantially normal anatomical configuration attached to the bioprosthesis 10.
- the length Lj of the coronary artery segments remaining after final trimming will be at least 2mm and typically in the range of 2-6 mm, while the length L 2 of the discarded distal coronary segments 19 is preferably less than 5 mm.
- the bioprosthesis 10 is sterilized by a suitable technique, such as immersion in a biocompatible sterilization solution. The bioprosthesis is then measured to determine its outside diameter, usually rounded off to the nearest millimeter. For commercial applications, bioprostheses 10 which have outside diameters which would round off to an odd number of millimeters (e.g., 15, 17, 19, 21, 23, 25 , 27 and 29 mm) may be rejected.
- a suitable technique such as immersion in a biocompatible sterilization solution.
- the bioprosthesis is then measured to determine its outside diameter, usually rounded off to the nearest millimeter.
- bioprostheses 10 which have outside diameters which would round off to an odd number of millimeters (e.g., 15, 17, 19, 21, 23, 25 , 27 and 29 mm) may be rejected.
- the bioprosthesis 10 After the bioprosthesis 10 has been sized, it is subjected to a second trimming step in which substantially all of the myocardial tissue is shaved away, leaving a thin cartilage rim adjacent to the right coronary septal shelf for reinforcement.
- the left and right coronary artery segments 14a, 14b are allowed to remain.
- All trimming is conducted with the goal leaving an intact aortic wall segment above the protruding coronary segments 14a, 14b, such intact aortic wall segment being of sufficient width to a) maintain proper alignment of the commissure, b) prevent distortion of the bioprosthesis 10 during suturing, and/or c) permit replacement of a supracoronary segment of the patient's ascending aorta (e.g., a "total root replacement") if so desired.
- a supracoronary segment of the patient's ascending aorta e.g., a "total root replacement
- the inflow end IE of the bioprosthesis 10 is trimmed on the same plane as the cusps of the valve leaflets 20, usually leaving an intact segment of about 3 to 4 mm in width as measured from the hinge of the leaflet. All of the fatty tissue in the aorta is trimmed away.
- the resulting aortic segment contains three valve leaflets 20, each of which is affixed to the aortic segment at a juncture.
- the inner edges 25 of the valve leaflets 20 meet when the leaflets 20 are in their closed positions, as shown in the drawings.
- the leaflets 20 form commissures at their junctions with the aortic wall, and the leaflets are joined to the aortic segment 12 along a leaflet junctures 29.
- the wall of the aortic segment 12 adjacent junctures 29 forms the Sinus of Nalsalva (not shown).
- the leaflet 20 closest to the right coronary artery segment 14a is positioned somewhat asymmetrically with respect to the other two leaflets 20.
- a fabric covering 28 may optionally be disposed about the inflow end IE of the bioprosthesis 10 and/or upon a portion of one side of the bioprosthesis 10 which corresponds to the right coronary septal shelf, as shown in Figure 1.
- This fabric covering 28 enhances the s 10 which is sutured to the native aortic annulus, and thus serves to deter the sutures from tearing through the tissue of the bioprosthesis 10.
- This fabric covering 28 may be formed of a thin, biocompatible material which is strong enough to hold sutures.
- such fabric covering 28 may be formed of woven polyester having a thickness of 0.008 inch" and a weight of 72 grams per square meter.
- the fabric used for the covering 28 is preferably cut on the diagonal to assure a snug fit around curved surfaces. The fabric is then sewn to the bioprosthesis 10 by hand, using a nonabsorbable, biocompatible thread.
- Mid-cusp markings 32 such as stitches formed of thread of a color which contrasts with the body of the bioprosthesis 10, may be formed on the fabric covering 28 along the inflow rim, preferably at the mid-cusp point of each leaflet 20, to aid the surgeon in aligning the bioprosthesis 10 with the patient's natural aorta.
- the markings 32 may be stitches of navy blue thread, and the like.
- An exemplary light green marking thread is Polyester PTFE-Coated thread of 6.0 size, having a denier of 110-130.
- Additional commissure markings 33 may also be formed on the fabric covering and/or inflow end of the bioprosthesis 10 at the locations of the valvular commissures to aid the surgeon in aligning the bioprosthesis with the patient's native anatomical structures. These optional commissure markings 33 may be formed in the same manner as described hereabove with respect to the mid-cusp markings 32, but will preferably of a color which is different from the mid-cusp markings 32 so as to permit the surgeon to easily distinguish between the mid-cusp markings 32 and commissure markings 33.
- a valve retainer fixture 34 may be attached to the outflow end OE of the bioprosthesis, as shown, to facilitate the attachment of an elongate handle thereto.
- valve retainer fixture 34 may be of the type described in United States Patent No. 5, 336, 258 (Quintero et al).
- the bioprosthesis may be mounted within a cage-like holding apparatus of the type described in copending United States Patent Application Serial No. 08/723,420, entitled Bioprosthetic Heart Valve Implantation Device.
- the currently used methods for surgical implantation of the bioprosthesis 10 of the present invention typically require that the patient be placed under general anesthesia and on cardiopulmonary bypass. An incision is made in the patient's chest wall (e.g., a median sternotomy) and the heart is exposed. The malfunctioning endogenous valve (typically the aortic valve but possibly another cardiac valve such as the pulmonary valve located between the right ventricle and the pulmonary artery) is then removed and the bioprosthesis 10 (or a portion thereof) is sutured into place to act as a prosthetic replacement for the previously-removed endogenous valve.
- the malfunctioning endogenous valve typically the aortic valve but possibly another cardiac valve such as the pulmonary valve located between the right ventricle and the pulmonary artery
- the bioprosthesis 10 shown in figures 1-4 will typically be implanted at the aortic position to replace the endogenous aortic heart valve. However, in some instances the bioprosthesis 10 may also be utilized to replace another heart valve such as a malfunctioning pulmonary valve located between the right ventricle and pulmonary artery.
- the lumens 15 a, 15b of the coronary segments 14a, 14b will typically be closed off by suitable closure means such as ligation, embolization, or placement of a purse string suture.
- a bioprosthesis 10 of appropriate size is selected and is either a) trimmed along marker thread 30 or at some other location selected by the surgeon to separate the aortic root portion of the bioprosthesis 10 (i.e., the base of the aortic segment 12 having the leaflets 20 disposed therein) from the remainder of its aortic segment 12 and coronary segments 14a, 14b or b) the lumens 15 of the coronary segments 14a, 14b are closed by ligation, placement of a purse string suture thereabout, embolization of other suitable means to prevent blood from subsequently leaking out of the lumens 15 of those coronary segments 14a, 14b.
- bioprosthesis 10 may be implanted at the aortic location to replace the patient's endogenous aortic valve, without attachment of coronary arteries or other vessels or grafts to the coronary segments 14a, 14b. ii. Total-Root Aortic Applications of the Bioprosthesis:
- the entire bioprosthesis 10, including the entire aortic segment 12 and coronary artery segments 14a, 14b may be implanted at the aortic location, in accordance with the procedure shown in Figures 5a-5c.
- the patient's right coronary artery RCA and left coronary artery LCA are transected at locations which are spaced distances away from the wall of the patient's ascending aorta AO and a segment of the patient's ascending aorta AO is removed and the native aortic valve leaflets are surgically excised and removed.
- a bioprosthesis 10 of correct size is selected, and a handle (not shown) is attached to the handle connection fixture.
- the handle (not shown) is then used to position the bioprosthesis 10 such that its inflow end IE is in juxtaposition to the aortic annulus, and a proximal anastomosis PA is formed to secure the inflow end IE of the bioprosthesis 10 to the native aortic annulus.
- the native right coronary artery RCA is trimmed to length, if necessary, and a right coronary anastomosis CAR is formed between the transected end of the right coronary artery RCA and the distal end of the right coronary segment 14a of the bioprosthesis 10.
- the native left coronary artery LCA is then trimmed to length, if necessary, and a left coronary anastomosis CAL is formed between the transected end of the left coronary artery LCA and the distal end of the left coronary segment 14b of the bioprosthesis 10.
- the patient's coronary arterial vasculature is thereby connected to the aortic segment 12 of the bioprosthesis 10 such that a portion of the arterial blood which subsequently flow is into the aortic segment 12 of the bioprosthesis 10 will flow into the right and left main coronary arteries RCA, LCA to perfuse the patient's myocardium in accordance with normal hemodynamics.
- a coronary artery bypass graft(s) one of more openings may be made in the aortic segment 12 of the bioprosthesis, and the ends of the bypass graft(s) may be sutured to such openings in accordance with well known surgical technique.
- the patient may be removed from cardiopulmonary bypass and the chest incision may be closed.
- the invention has been described hereabove with reference to certain presently preferred embodiments only, and no attempt has been made to exhaustively describe all possible embodiments of the invention.
- a minimal access e.g. "keyhole”
- a minimal access e.g. "keyhole”
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002315718A CA2315718C (en) | 1997-12-24 | 1998-12-11 | Stentless bioprosthetic heart valve with coronary protuberances |
DE69834945T DE69834945T2 (en) | 1997-12-24 | 1998-12-11 | SUPPORTING RINGLESS BIOPROTHETIC HEARTED CAP WITH CORONARY INCREASES |
EP98960843A EP1041942B1 (en) | 1997-12-24 | 1998-12-11 | Stentless bioprosthetic heart valve with coronary protuberances |
AU16345/99A AU728106B2 (en) | 1997-12-24 | 1998-12-11 | Stentless bioprosthetic heart valve with coronary protuberances |
JP2000526173A JP3775991B2 (en) | 1997-12-24 | 1998-12-11 | Stentless heart valve bioprosthesis with coronary ridge |
BR9814491-0A BR9814491A (en) | 1997-12-24 | 1998-12-11 | Heart valve bioprosthesis without stent, and, processes for total root replacement of an endogenous aortic heart valve in a mammalian patient, and for surgical replacement of a heart valve and an adjacent vascular tissue segment in a mammalian patient |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/998,318 US6001126A (en) | 1997-12-24 | 1997-12-24 | Stentless bioprosthetic heart valve with coronary protuberances and related methods for surgical repair of defective heart valves |
US08/998,318 | 1997-12-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999033412A1 true WO1999033412A1 (en) | 1999-07-08 |
Family
ID=25545049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/026344 WO1999033412A1 (en) | 1997-12-24 | 1998-12-11 | Stentless bioprosthetic heart valve with coronary protuberances |
Country Status (8)
Country | Link |
---|---|
US (2) | US6001126A (en) |
EP (1) | EP1041942B1 (en) |
JP (2) | JP3775991B2 (en) |
AU (1) | AU728106B2 (en) |
BR (1) | BR9814491A (en) |
CA (1) | CA2315718C (en) |
DE (1) | DE69834945T2 (en) |
WO (1) | WO1999033412A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001056511A1 (en) * | 2000-02-03 | 2001-08-09 | Medos Medizintechnik Ag | Stentless heart valve bioprosthesis |
US6682558B2 (en) | 2001-05-10 | 2004-01-27 | 3F Therapeutics, Inc. | Delivery system for a stentless valve bioprosthesis |
WO2008044958A1 (en) * | 2006-10-11 | 2008-04-17 | Rosseykin Yevgeniy Vladimirovi | Frameless aortic root prosthesis |
WO2009104000A1 (en) * | 2008-02-22 | 2009-08-27 | Barts And The London Nhs Trust | Blood vessel prosthesis and delivery apparatus |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6077214A (en) * | 1998-07-29 | 2000-06-20 | Myocor, Inc. | Stress reduction apparatus and method |
US6183411B1 (en) | 1998-09-21 | 2001-02-06 | Myocor, Inc. | External stress reduction device and method |
US7883539B2 (en) | 1997-01-02 | 2011-02-08 | Edwards Lifesciences Llc | Heart wall tension reduction apparatus and method |
US6406420B1 (en) | 1997-01-02 | 2002-06-18 | Myocor, Inc. | Methods and devices for improving cardiac function in hearts |
US6050936A (en) | 1997-01-02 | 2000-04-18 | Myocor, Inc. | Heart wall tension reduction apparatus |
US6332893B1 (en) | 1997-12-17 | 2001-12-25 | Myocor, Inc. | Valve to myocardium tension members device and method |
US6260552B1 (en) | 1998-07-29 | 2001-07-17 | Myocor, Inc. | Transventricular implant tools and devices |
US6254564B1 (en) | 1998-09-10 | 2001-07-03 | Percardia, Inc. | Left ventricular conduit with blood vessel graft |
PL211860B1 (en) * | 2000-01-31 | 2012-07-31 | Cook Biotech Inc | Valve stent system |
DE10190290B4 (en) * | 2000-02-03 | 2008-06-26 | Auto Tissue Gmbh | Scaffold-free (stentless) heart valve bioprosthesis |
DE10010073B4 (en) | 2000-02-28 | 2005-12-22 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anchoring for implantable heart valve prostheses |
DE10010074B4 (en) | 2000-02-28 | 2005-04-14 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Device for fastening and anchoring heart valve prostheses |
US6537198B1 (en) | 2000-03-21 | 2003-03-25 | Myocor, Inc. | Splint assembly for improving cardiac function in hearts, and method for implanting the splint assembly |
US6458155B1 (en) | 2000-09-01 | 2002-10-01 | Edwards Lifesciences Corporation | Fresh donor heart valve sizer and method of use |
US6616684B1 (en) | 2000-10-06 | 2003-09-09 | Myocor, Inc. | Endovascular splinting devices and methods |
US6723038B1 (en) | 2000-10-06 | 2004-04-20 | Myocor, Inc. | Methods and devices for improving mitral valve function |
US8038708B2 (en) | 2001-02-05 | 2011-10-18 | Cook Medical Technologies Llc | Implantable device with remodelable material and covering material |
FR2828263B1 (en) | 2001-08-03 | 2007-05-11 | Philipp Bonhoeffer | DEVICE FOR IMPLANTATION OF AN IMPLANT AND METHOD FOR IMPLANTATION OF THE DEVICE |
PT1423066E (en) | 2001-09-07 | 2008-09-29 | Mardil Inc | Method and apparatus for external heart stabilization |
US6764510B2 (en) | 2002-01-09 | 2004-07-20 | Myocor, Inc. | Devices and methods for heart valve treatment |
US6830586B2 (en) | 2002-02-28 | 2004-12-14 | 3F Therapeutics, Inc. | Stentless atrioventricular heart valve fabricated from a singular flat membrane |
US7125418B2 (en) * | 2002-04-16 | 2006-10-24 | The International Heart Institute Of Montana Foundation | Sigmoid valve and method for its percutaneous implantation |
US7247134B2 (en) | 2002-11-12 | 2007-07-24 | Myocor, Inc. | Devices and methods for heart valve treatment |
US7112219B2 (en) | 2002-11-12 | 2006-09-26 | Myocor, Inc. | Devices and methods for heart valve treatment |
US20040153145A1 (en) * | 2002-11-26 | 2004-08-05 | Clemson University | Fixation method for bioprostheses |
US7189259B2 (en) * | 2002-11-26 | 2007-03-13 | Clemson University | Tissue material and process for bioprosthesis |
US7717952B2 (en) * | 2003-04-24 | 2010-05-18 | Cook Incorporated | Artificial prostheses with preferred geometries |
US8221492B2 (en) | 2003-04-24 | 2012-07-17 | Cook Medical Technologies | Artificial valve prosthesis with improved flow dynamics |
US7367984B2 (en) * | 2003-05-07 | 2008-05-06 | Medtronic, Inc. | Methods and apparatus for sizing fresh donor heart valves |
US20090132035A1 (en) * | 2004-02-27 | 2009-05-21 | Roth Alex T | Prosthetic Heart Valves, Support Structures and Systems and Methods for Implanting the Same |
US20070073387A1 (en) * | 2004-02-27 | 2007-03-29 | Forster David C | Prosthetic Heart Valves, Support Structures And Systems And Methods For Implanting The Same |
EP1722711A4 (en) * | 2004-02-27 | 2009-12-02 | Aortx Inc | Prosthetic heart valve delivery systems and methods |
WO2005096988A1 (en) * | 2004-04-01 | 2005-10-20 | Cook Incorporated | A device for retracting the walls of a body vessel with remodelable material |
EP1737390A1 (en) * | 2004-04-08 | 2007-01-03 | Cook Incorporated | Implantable medical device with optimized shape |
US7465316B2 (en) * | 2004-04-12 | 2008-12-16 | Boston Scientific Scimed, Inc. | Tri-petaled aortic root vascular graft |
US7758633B2 (en) * | 2004-04-12 | 2010-07-20 | Boston Scientific Scimed, Inc. | Varied diameter vascular graft |
US7309461B2 (en) * | 2004-04-12 | 2007-12-18 | Boston Scientific Scimed, Inc. | Ultrasonic crimping of a varied diameter vascular graft |
US20060052867A1 (en) | 2004-09-07 | 2006-03-09 | Medtronic, Inc | Replacement prosthetic heart valve, system and method of implant |
US20060190017A1 (en) * | 2004-11-19 | 2006-08-24 | Cyr John S | Fibrin sealants and platelet concentrates applied to effect hemostasis at the interface of an implantable medical device with body tissue |
DE102005003632A1 (en) | 2005-01-20 | 2006-08-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Catheter for the transvascular implantation of heart valve prostheses |
CA2609022C (en) * | 2005-05-20 | 2010-07-20 | The Cleveland Clinic Foundation | Apparatus and methods for repairing the function of a diseased valve and method for making same |
DE102005051849B4 (en) | 2005-10-28 | 2010-01-21 | JenaValve Technology Inc., Wilmington | Device for implantation and attachment of heart valve prostheses |
DE102005052628B4 (en) | 2005-11-04 | 2014-06-05 | Jenavalve Technology Inc. | Self-expanding, flexible wire mesh with integrated valvular prosthesis for the transvascular heart valve replacement and a system with such a device and a delivery catheter |
US20070213813A1 (en) | 2005-12-22 | 2007-09-13 | Symetis Sa | Stent-valves for valve replacement and associated methods and systems for surgery |
US7749266B2 (en) * | 2006-02-27 | 2010-07-06 | Aortx, Inc. | Methods and devices for delivery of prosthetic heart valves and other prosthetics |
US8147541B2 (en) * | 2006-02-27 | 2012-04-03 | Aortx, Inc. | Methods and devices for delivery of prosthetic heart valves and other prosthetics |
US7625403B2 (en) | 2006-04-04 | 2009-12-01 | Medtronic Vascular, Inc. | Valved conduit designed for subsequent catheter delivered valve therapy |
US7524331B2 (en) | 2006-04-06 | 2009-04-28 | Medtronic Vascular, Inc. | Catheter delivered valve having a barrier to provide an enhanced seal |
US7740655B2 (en) | 2006-04-06 | 2010-06-22 | Medtronic Vascular, Inc. | Reinforced surgical conduit for implantation of a stented valve therein |
US7591848B2 (en) | 2006-04-06 | 2009-09-22 | Medtronic Vascular, Inc. | Riveted stent valve for percutaneous use |
US20070239269A1 (en) * | 2006-04-07 | 2007-10-11 | Medtronic Vascular, Inc. | Stented Valve Having Dull Struts |
US20070244545A1 (en) * | 2006-04-14 | 2007-10-18 | Medtronic Vascular, Inc. | Prosthetic Conduit With Radiopaque Symmetry Indicators |
US20070244544A1 (en) * | 2006-04-14 | 2007-10-18 | Medtronic Vascular, Inc. | Seal for Enhanced Stented Valve Fixation |
US20070244546A1 (en) * | 2006-04-18 | 2007-10-18 | Medtronic Vascular, Inc. | Stent Foundation for Placement of a Stented Valve |
US8585594B2 (en) * | 2006-05-24 | 2013-11-19 | Phoenix Biomedical, Inc. | Methods of assessing inner surfaces of body lumens or organs |
CN101506538A (en) | 2006-06-20 | 2009-08-12 | 奥尔特克斯公司 | Torque shaft and torque drive |
US20090209955A1 (en) * | 2006-06-20 | 2009-08-20 | Forster David C | Prosthetic valve implant site preparation techniques |
CA2657442A1 (en) * | 2006-06-20 | 2007-12-27 | Aortx, Inc. | Prosthetic heart valves, support structures and systems and methods for implanting the same |
CA2657446A1 (en) * | 2006-06-21 | 2007-12-27 | Aortx, Inc. | Prosthetic valve implantation systems |
CA2661959A1 (en) * | 2006-09-06 | 2008-03-13 | Aortx, Inc. | Prosthetic heart valves, systems and methods of implanting |
US8142805B1 (en) | 2006-11-06 | 2012-03-27 | Clemson University Research Foundation | Implantable devices including fixed tissues |
US8388679B2 (en) | 2007-01-19 | 2013-03-05 | Maquet Cardiovascular Llc | Single continuous piece prosthetic tubular aortic conduit and method for manufacturing the same |
US9138315B2 (en) | 2007-04-13 | 2015-09-22 | Jenavalve Technology Gmbh | Medical device for treating a heart valve insufficiency or stenosis |
US7896915B2 (en) | 2007-04-13 | 2011-03-01 | Jenavalve Technology, Inc. | Medical device for treating a heart valve insufficiency |
EP3150171A1 (en) | 2007-05-15 | 2017-04-05 | JenaValve Technology, Inc. | Handle for manipulating a catheter tip, catheter system and medical insertion system for inserting a self-expandalbe heart valve stent |
US7846199B2 (en) * | 2007-11-19 | 2010-12-07 | Cook Incorporated | Remodelable prosthetic valve |
US8398704B2 (en) | 2008-02-26 | 2013-03-19 | Jenavalve Technology, Inc. | Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient |
US9044318B2 (en) | 2008-02-26 | 2015-06-02 | Jenavalve Technology Gmbh | Stent for the positioning and anchoring of a valvular prosthesis |
US9168130B2 (en) | 2008-02-26 | 2015-10-27 | Jenavalve Technology Gmbh | Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient |
US8317858B2 (en) | 2008-02-26 | 2012-11-27 | Jenavalve Technology, Inc. | Stent for the positioning and anchoring of a valvular prosthesis in an implantation site in the heart of a patient |
BR112012021347A2 (en) | 2008-02-26 | 2019-09-24 | Jenavalve Tecnology Inc | stent for positioning and anchoring a valve prosthesis at an implantation site in a patient's heart |
US8465540B2 (en) | 2008-02-26 | 2013-06-18 | Jenavalve Technology, Inc. | Stent for the positioning and anchoring of a valvular prosthesis |
US20100292779A1 (en) | 2009-05-15 | 2010-11-18 | Helmut Straubinger | Device for compressing a stent and a system as well as a method for loading a stent into a medical delivery system |
US10856978B2 (en) | 2010-05-20 | 2020-12-08 | Jenavalve Technology, Inc. | Catheter system |
US11278406B2 (en) | 2010-05-20 | 2022-03-22 | Jenavalve Technology, Inc. | Catheter system for introducing an expandable heart valve stent into the body of a patient, insertion system with a catheter system and medical device for treatment of a heart valve defect |
CN103002833B (en) | 2010-05-25 | 2016-05-11 | 耶拿阀门科技公司 | Artificial heart valve and comprise artificial heart valve and support through conduit carry interior prosthese |
US8696741B2 (en) | 2010-12-23 | 2014-04-15 | Maquet Cardiovascular Llc | Woven prosthesis and method for manufacturing the same |
JP6005168B2 (en) | 2011-10-21 | 2016-10-12 | イエナバルブ テクノロジー インク | Catheter system for introducing an expandable heart valve stent into a patient's body, insertion system equipped with a catheter system, and medical device for treating heart valve defects |
WO2013120082A1 (en) | 2012-02-10 | 2013-08-15 | Kassab Ghassan S | Methods and uses of biological tissues for various stent and other medical applications |
DE202013011734U1 (en) | 2012-05-16 | 2014-04-29 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | A catheter delivery system for inserting an expandable heart valve prosthesis and a medical device for treating a valvular defect |
US9301835B2 (en) | 2012-06-04 | 2016-04-05 | Edwards Lifesciences Corporation | Pre-assembled bioprosthetic valve and sealed conduit |
CN102670333A (en) * | 2012-06-08 | 2012-09-19 | 同济大学 | Aortic valve stent with coronary artery and conveyor of same |
US9585748B2 (en) | 2012-09-25 | 2017-03-07 | Edwards Lifesciences Corporation | Methods for replacing a native heart valve and aorta with a prosthetic heart valve and conduit |
US9844436B2 (en) | 2012-10-26 | 2017-12-19 | Edwards Lifesciences Corporation | Aortic valve and conduit graft implant tool |
EP2953580A2 (en) | 2013-02-11 | 2015-12-16 | Cook Medical Technologies LLC | Expandable support frame and medical device |
JP6563394B2 (en) | 2013-08-30 | 2019-08-21 | イェーナヴァルヴ テクノロジー インコーポレイテッド | Radially foldable frame for an artificial valve and method for manufacturing the frame |
US10119882B2 (en) | 2015-03-10 | 2018-11-06 | Edwards Lifesciences Corporation | Surgical conduit leak testing |
JP6767388B2 (en) | 2015-05-01 | 2020-10-14 | イェーナヴァルヴ テクノロジー インコーポレイテッド | Devices and methods to reduce the proportion of pacemakers in heart valve replacement |
EP4183371A1 (en) | 2016-05-13 | 2023-05-24 | JenaValve Technology, Inc. | Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system |
WO2018138658A1 (en) | 2017-01-27 | 2018-08-02 | Jenavalve Technology, Inc. | Heart valve mimicry |
RU2698983C2 (en) * | 2017-12-20 | 2019-09-02 | Общество с ограниченной ответственностью "Кардиотехника" | Method of making valve bioprotesis of heart valve on flexible base framework with low profile |
US11337805B2 (en) | 2018-01-23 | 2022-05-24 | Edwards Lifesciences Corporation | Prosthetic valve holders, systems, and methods |
USD908874S1 (en) | 2018-07-11 | 2021-01-26 | Edwards Lifesciences Corporation | Collapsible heart valve sizer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5089015A (en) * | 1989-11-28 | 1992-02-18 | Promedica International | Method for implanting unstented xenografts and allografts |
WO1992003990A1 (en) * | 1990-09-07 | 1992-03-19 | Baxter International Inc. | Stentless heart valve and holder |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1127325A (en) * | 1965-08-23 | 1968-09-18 | Henry Berry | Improved instrument for inserting artificial heart valves |
US3548418A (en) * | 1968-05-03 | 1970-12-22 | Cutter Lab | Graft valve transplantation for human hearts and graft-support ring therefor |
US4050893A (en) * | 1974-07-22 | 1977-09-27 | Hancock Laboratories, Inc. | Arrangement for preparing natural tissue for implantation |
US4056854A (en) * | 1976-09-28 | 1977-11-08 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Aortic heart valve catheter |
US4185636A (en) * | 1977-12-29 | 1980-01-29 | Albert Einstein College Of Medicine Of Yeshiva University | Suture organizer, prosthetic device holder, and related surgical procedures |
US4182446A (en) * | 1978-06-12 | 1980-01-08 | Hancock Laboratories, Inc. | Heart valve holder |
US4372743A (en) * | 1981-06-22 | 1983-02-08 | American Hospital Supply Corp. | Low-pressure fixation of valvular tissue intended for implantation |
US4350492A (en) * | 1981-08-24 | 1982-09-21 | Vascor, Inc. | Method for preparing tissue heart valve |
US4865600A (en) * | 1981-08-25 | 1989-09-12 | Baxter International Inc. | Mitral valve holder |
US7018407B1 (en) * | 1981-10-29 | 2006-03-28 | Medtronic | Valve holder for tricuspid heart valve |
JPS60500014A (en) | 1982-11-12 | 1985-01-10 | バツクスター トラベノル ラボラトリーズ インコーポレーテツド | Chemical sterilization of biological tissue ready for transplantation |
IL74460A (en) * | 1983-09-02 | 1990-01-18 | Istec Ind & Technologies Ltd | Surgical implement particularly useful for suturing prosthetic valves |
JPH0411715Y2 (en) * | 1985-08-30 | 1992-03-24 | ||
US5352240A (en) * | 1989-05-31 | 1994-10-04 | Promedica International, Inc. | Human heart valve replacement with porcine pulmonary valve |
AU626686B2 (en) | 1989-06-09 | 1992-08-06 | Medtronic, Inc. | Dynamic fixation of porcine aortic valves |
DE69224852T2 (en) * | 1991-08-29 | 1998-11-12 | Medtronic Inc | FIXING A HEART VALVE OF NATURAL TISSUE |
US5449384A (en) | 1992-09-28 | 1995-09-12 | Medtronic, Inc. | Dynamic annulus heart valve employing preserved porcine valve leaflets |
GB9324201D0 (en) * | 1993-11-24 | 1994-01-12 | London Health Ass | Stentless heart valve surgical support device |
US5549666A (en) | 1994-09-02 | 1996-08-27 | Baxter International Inc. | Natural tissue valve prostheses having variably complaint leaflets |
US5728152A (en) * | 1995-06-07 | 1998-03-17 | St. Jude Medical, Inc. | Bioresorbable heart valve support |
-
1997
- 1997-12-24 US US08/998,318 patent/US6001126A/en not_active Expired - Lifetime
-
1998
- 1998-12-11 DE DE69834945T patent/DE69834945T2/en not_active Expired - Lifetime
- 1998-12-11 EP EP98960843A patent/EP1041942B1/en not_active Expired - Lifetime
- 1998-12-11 CA CA002315718A patent/CA2315718C/en not_active Expired - Lifetime
- 1998-12-11 BR BR9814491-0A patent/BR9814491A/en not_active IP Right Cessation
- 1998-12-11 WO PCT/US1998/026344 patent/WO1999033412A1/en active IP Right Grant
- 1998-12-11 JP JP2000526173A patent/JP3775991B2/en not_active Expired - Lifetime
- 1998-12-11 AU AU16345/99A patent/AU728106B2/en not_active Ceased
-
1999
- 1999-12-14 US US09/461,304 patent/US6342070B1/en not_active Expired - Lifetime
-
2005
- 2005-05-20 JP JP2005147913A patent/JP2005230580A/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5089015A (en) * | 1989-11-28 | 1992-02-18 | Promedica International | Method for implanting unstented xenografts and allografts |
WO1992003990A1 (en) * | 1990-09-07 | 1992-03-19 | Baxter International Inc. | Stentless heart valve and holder |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001056511A1 (en) * | 2000-02-03 | 2001-08-09 | Medos Medizintechnik Ag | Stentless heart valve bioprosthesis |
US6682558B2 (en) | 2001-05-10 | 2004-01-27 | 3F Therapeutics, Inc. | Delivery system for a stentless valve bioprosthesis |
WO2008044958A1 (en) * | 2006-10-11 | 2008-04-17 | Rosseykin Yevgeniy Vladimirovi | Frameless aortic root prosthesis |
WO2009104000A1 (en) * | 2008-02-22 | 2009-08-27 | Barts And The London Nhs Trust | Blood vessel prosthesis and delivery apparatus |
US9439758B2 (en) | 2008-02-22 | 2016-09-13 | Barts And The London Nhs Trust | Blood vessel prosthesis and delivery apparatus |
Also Published As
Publication number | Publication date |
---|---|
BR9814491A (en) | 2000-10-10 |
JP3775991B2 (en) | 2006-05-17 |
US6342070B1 (en) | 2002-01-29 |
CA2315718A1 (en) | 1999-07-08 |
AU1634599A (en) | 1999-07-19 |
JP2005230580A (en) | 2005-09-02 |
EP1041942B1 (en) | 2006-06-14 |
DE69834945D1 (en) | 2006-07-27 |
EP1041942A1 (en) | 2000-10-11 |
DE69834945T2 (en) | 2006-10-19 |
CA2315718C (en) | 2004-09-14 |
US6001126A (en) | 1999-12-14 |
JP2001526932A (en) | 2001-12-25 |
AU728106B2 (en) | 2001-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6001126A (en) | Stentless bioprosthetic heart valve with coronary protuberances and related methods for surgical repair of defective heart valves | |
AU718295B2 (en) | Physiologic mitral valve bioprosthesis | |
US6797000B2 (en) | Tri-composite, full root, stentless valve | |
AU734858B2 (en) | System, apparatus and method for chemical fixation of stentless cardiac valvular bioprostheses | |
US5509930A (en) | Stentless heart valve | |
US7160320B2 (en) | Reed valve for implantation into mammalian blood vessels and heart with optional temporary or permanent support | |
CN102869320B (en) | Can percutaneous conveying cardiac valve and related manufacturing processes | |
US5861028A (en) | Natural tissue heart valve and stent prosthesis and method for making the same | |
JP2002541974A (en) | Heart substitute valve | |
US20070038294A1 (en) | Method and apparatus for replacing a mitral valve and an aortic valve with a homograft | |
JP2004520100A (en) | Valved stent and method of use | |
US6524339B1 (en) | Cryopreserved homografts and other stentless bioprosthetic heart valves having natural tissue sewing rings | |
WO2009156471A1 (en) | Prosthetic heart valve and method for making such a valve | |
Noishiki et al. | Development and evaluation of a pliable biological valved conduit. Part I: preparation, biochemical properties, and histological findings | |
Hopkins et al. | Stentless Xenograft Valves | |
Hopkins et al. | “Miniroot” Replacement Techniques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 16345/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2315718 Country of ref document: CA Ref country code: CA Ref document number: 2315718 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 526173 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998960843 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998960843 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 16345/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998960843 Country of ref document: EP |